

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8176242

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
AVELAS (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC		03/23/2023
RECEIVING PARTY DATA		
Name:	AVELAS ACQUISITION CORPORATION	
Street Address:	11099 NORTH TORREY PINES ROAD, SUITE 290	
City:	LA JOLLA	
State/Country:	CALIFORNIA	
Postal Code:	92037	
PROPERTY NUMBERS Total: 17		
Property Type	Number	
Application Number:	13819312	
Application Number:	14736194	
Application Number:	14235522	
Application Number:	15006832	
Application Number:	15132773	
Application Number:	15295482	
Application Number:	15806246	
Application Number:	16228488	
Application Number:	14764681	
Application Number:	15685942	
Application Number:	16264296	
Application Number:	17302453	
Application Number:	17930259	
Application Number:	16603200	
Application Number:	17048078	
Application Number:	17048080	
Application Number:	18248839	
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent</i>		
PATENT		

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (415) 733-6000
Email: jhuddleston@goodwinlaw.com
Correspondent Name: GOODWIN PROCTER LLP
Address Line 1: THREE EMBARCADERO CENTER
Address Line 4: SAN FRANCISCO, CALIFORNIA 94111

ATTORNEY DOCKET NUMBER:	AVS-000
--------------------------------	---------

NAME OF SUBMITTER:	JENNIFFER HUDDLESTON
---------------------------	----------------------

SIGNATURE:	/Jenniffer C. Huddleston/
-------------------	---------------------------

DATE SIGNED:	09/19/2023
---------------------	------------

Total Attachments: 9

source=Confirmatory Patent Assignment_Avelas LLC to AAC_Signed#page1.tif
source=Confirmatory Patent Assignment_Avelas LLC to AAC_Signed#page2.tif
source=Confirmatory Patent Assignment_Avelas LLC to AAC_Signed#page3.tif
source=Confirmatory Patent Assignment_Avelas LLC to AAC_Signed#page4.tif
source=Confirmatory Patent Assignment_Avelas LLC to AAC_Signed#page5.tif
source=Confirmatory Patent Assignment_Avelas LLC to AAC_Signed#page6.tif
source=Confirmatory Patent Assignment_Avelas LLC to AAC_Signed#page7.tif
source=Confirmatory Patent Assignment_Avelas LLC to AAC_Signed#page8.tif
source=Confirmatory Patent Assignment_Avelas LLC to AAC_Signed#page9.tif

CONFIRMATORY CORPORATE ASSIGNMENT

THIS CONFIRMATORY ASSIGNMENT is made this 9th day of March 2023, by and between Avelas Acquisition Corporation, a corporation organized under and pursuant to the laws of the State of Delaware having its principal place of business at 11099 North Torrey Pines Rd, Suite 290, La Jolla, California 92037 (hereinafter referred to as "Assignee") and Avelas (assignment for the benefit of creditors) LLC, a limited liability company organized under and pursuant to the laws of the State of California having its principal place of business at 3945 Freedom Circle, Suite 560, Santa Clara, California 95054, in its sole and limited capacity as assignee for the benefit of creditors of Avelas Biosciences, Inc. (hereinafter referred to as "Assignor").

WHEREAS, Assignor and Assignee entered into an Asset Purchase Agreement, dated December 13, 2022 (hereinafter, the "Agreement") under which Assignor agreed to and did assign the patents and patent applications listed in Purchased Assets Exhibit 1.2, Schedule 1 attached hereto (the "Application(s)") and any inventions contained therein;

WHEREAS, Assignor and Assignee desire to confirm Assignee's ownership of the entire right, title and interest in and to (a) said inventions and all embodiments thereof; and (b)(i) the Application(s), (ii) all United States, foreign, or international patent applications, including those filed under the Paris Convention for the Protection of Industrial Property, the Patent Cooperation Treaty or otherwise, that claim priority to or from the Application(s), including any divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application, (iii) each and every patent, utility model, or equivalent forms of protection thereto, including certification of invention, or inventor's certificate, granted or issued from any of the foregoing under subclause (ii), and (iv) each and every reissue, reexamination, renewal or extension of any kind of any patent of subclause (iii) (collectively, the "Patents").

NOW, THEREFORE, for good, valuable and sufficient consideration, receipt of which is hereby acknowledged by the Assignor, said Assignor confirms it has sold, assigned, transferred and conveyed unto said Assignee, its successors, legal representatives and assigns, or to the extent that such transfer has not been affected, does hereby sell, assign, transfer and

convey unto said Assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to (a) said inventions, (b) the Patents, including the right to claim priority to and from said Patents, and (c) all claims for past, present and future infringement of the Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Patents.

Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treat. Such cooperation by said Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Patents; (d) for interference or other priority proceedings involving said inventions or Patents; and (e) for legal proceedings involving said inventions or Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions.

The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Assignor, their respective heirs, legal representatives and assigns.

Said Assignor hereby warrants, represents and covenants that said Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

Said Assignor hereby requests that any Patents issuing or granting in the United States, any foreign country, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

This instrument will be interpreted and construed in accordance with the laws of the State of California without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.


IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument
to said Assignee as of the dates written below:

Assignor:

Avelas (assignment for the benefit of creditors)
LLC, solely as assignee for the benefit of
creditors of Avelas Biosciences, Inc.

Date: 3/23/2023

Signature: _____


Name: Michael Maidy, in his sole and limited capacity
Title: as Manager of Avelas (assignment for the
benefit of creditors), LLC, the assignee for
Avelas Biosciences, Inc.

Received and Agreed to by Assignee:
Avelas Acquisition Corporation

Date: 3/9/23

Signature: _____


Name: Jai Linton
Title: President CEO

Purchased Assets Exhibit 1.2
Schedule 1

Filed Patents

#	Case Number	Country	Title	Status	Application No.	Filing Date	Patent No.	Issue Date	Owner	Subject Matter
1	AVS-005	EP	COMPOSITIONS FOR LABELING NERVES AND METHODS OF USE	Allowed	11822751.1	9/2/2011			Avelas Biosciences, Inc.	Nerve labeling
2	AVS-005		COMPOSITIONS FOR LABELING NERVES AND METHODS OF USE	Issued	12/819,312	4/25/2013	9,072,773	7/7/2015	Avelas Biosciences, Inc.	Nerve labeling
3	AVS-005	C1	COMPOSITIONS FOR LABELING NERVES AND METHODS OF USE	Issued	14/736,194	6/10/2015	9,353,154	5/31/2016	Avelas Biosciences, Inc.	Nerve labeling
4	AVS-005	CA	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Pending	2,841,249	7/27/2012			Avelas Biosciences, Inc.	AVB-620
5	AVS-005	JP	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	2014-523099	7/27/2012	6124150	4/14/2017	Avelas Biosciences, Inc.	AVB-620
6	AVS-005	AU	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	2012290318	7/27/2012	2012290318	12/15/2016	Avelas Biosciences, Inc.	AVB-620
7	AVS-005	CN	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	201280047936 9	7/27/2012	ZL201280047936 9	11/16/2016	Avelas Biosciences, Inc.	AVB-620
8	AVS-005	KR	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	10-2014-7002685	7/27/2012	2004558	7/22/2019	Avelas Biosciences, Inc.	AVB-620
9	AVS-005	EA	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	201490385	7/27/2012	030795	9/28/2018	Avelas Biosciences, Inc.	AVB-620
10	AVS-005	MX	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	MX/a/2014/001138	7/27/2012	350082	8/24/2017	Avelas Biosciences, Inc.	AVB-620
11	AVS-005	HK	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	14110740.6	7/27/2012	1197184	9/27/2019	Avelas Biosciences, Inc.	AVB-620
12	AVS-005		SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Issued	14/235,522	9/18/2014	9,278,144	3/8/2016	Avelas Biosciences, Inc.	AVB-620
13	AVS-005	C1	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Issued	15/006,832	1/26/2016	9,371,367	5/21/2016	Avelas Biosciences, Inc.	AVB-620
14	AVS-005	C2	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Issued	15/132,773	4/19/2016	9,504,763	11/29/2016	Avelas Biosciences, Inc.	AVB-620
15	AVS-005	C3	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Issued	15/295,482	10/17/2016	9,840,537	12/12/2017	Avelas Biosciences, Inc.	AVB-620
16	AVS-005	C4	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Issued	15/806,246	11/7/2017	10,239,919	3/26/2019	Avelas Biosciences, Inc.	AVB-620
17	AVS-005	CS	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Issued	16/228,488	12/20/2018	10,570,178	2/25/2020	Avelas Biosciences, Inc.	AVB-620
18	AVS-005	EP	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	12820320.5	7/27/2012	2736533	7/4/2018	Avelas Biosciences, Inc.	AVB-620
19	AVS-005	GB	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	12820320.5	7/27/2012	2736533	7/4/2018	Avelas Biosciences, Inc.	AVB-620
20	AVS-005	FR	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	12820320.5	7/27/2012	2736533	7/4/2018	Avelas Biosciences, Inc.	AVB-620
21	AVS-005	DE	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	12820320.5	7/27/2012	2736533	7/4/2018	Avelas Biosciences, Inc.	AVB-620
22	AVS-005	IT	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	12820320.5	7/27/2012	2736533	7/4/2018	Avelas Biosciences, Inc.	AVB-620
23	AVS-005	ES	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	12820320.5	7/27/2012	2736533	7/4/2018	Avelas Biosciences, Inc.	AVB-620
24	AVS-005	BE	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	12820320.5	7/27/2012	2736533	7/4/2018	Avelas Biosciences, Inc.	AVB-620
25	AVS-005	CH	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	12820320.5	7/27/2012	2736533	7/4/2018	Avelas Biosciences, Inc.	AVB-620
26	AVS-005	AT	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	12820320.5	7/27/2012	2736533	7/4/2018	Avelas Biosciences, Inc.	AVB-620
27	AVS-005	NL	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	12820320.5	7/27/2012	2736533	7/4/2018	Avelas Biosciences, Inc.	AVB-620
28	AVS-005	NO	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	12820320.5	7/27/2012	2736533	7/4/2018	Avelas Biosciences, Inc.	AVB-620
29	AVS-005	SE	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	12820320.5	7/27/2012	2736533	7/4/2018	Avelas Biosciences, Inc.	AVB-620

30	AVS-006	IE	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	12820320.5	7/27/2012	2736533	7/4/2018	Avelas Biosciences, Inc.	AVB-620
31	AVS-006	DK	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	12820320.5	7/27/2012	2736533	7/4/2018	Avelas Biosciences, Inc.	AVB-620
32	AVS-006	FI	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	12820320.5	7/27/2012	2736533	7/4/2018	Avelas Biosciences, Inc.	AVB-620
33	AVS-006	EPD1	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Pending	18181420.3	7/27/2012			Avelas Biosciences, Inc.	AVB-620
34	AVS-008	EP	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Pending	14746840.9	1/30/2014			Avelas Biosciences, Inc.	Cancer Imaging Compositions
35	AVS-008	CN	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	201480019153.9	1/30/2014	105102484	3/10/2020	Avelas Biosciences, Inc.	Cancer Imaging Compositions
36	AVS-008	JP	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	2015-556140	1/30/2014	6508781	4/12/2019	Avelas Biosciences, Inc.	Cancer Imaging Compositions
37	AVS-008	CA	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	2899448	1/30/2014	2899448	10/26/2021	Avelas Biosciences, Inc.	Cancer Imaging Compositions
38	AVS-008	CAD1	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Pending	3128911	8/25/2021			Avelas Biosciences, Inc.	Cancer Imaging Compositions
39	AVS-008	AU	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	2014212308	1/30/2014	2014212308	11/22/2018	Avelas Biosciences, Inc.	Cancer Imaging Compositions
40	AVS-008	EA	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	201591284	1/30/2014	031930	3/29/2019	Avelas Biosciences, Inc.	Cancer Imaging Compositions
41	AVS-008	KR	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	10-2015-7022729	1/30/2014	2278630	7/12/2021	Avelas Biosciences, Inc.	Cancer Imaging Compositions
42	AVS-008	KRD1	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	10-2021-7021841	7/12/2021	2363779	2/11/2022	Avelas Biosciences, Inc.	Cancer Imaging Compositions
43	AVS-008	MX	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	MX/a/2015/009858	1/30/2014	366375	7/5/2019	Avelas Biosciences, Inc.	Cancer Imaging Compositions
44	AVS-008	IN	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Granted	6336/DELNP/2015	1/30/2014	375520	8/26/2021	Avelas Biosciences, Inc.	Cancer Imaging Compositions
45	AVS-008	HK	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Pending	16105781.4	1/30/2014			Avelas Biosciences, Inc.	Cancer Imaging Compositions
46	AVS-008		SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Issued	14/764,681	7/30/2015	9,782,498	10/10/2017	Avelas Biosciences, Inc.	Cancer Imaging Compositions
47	AVS-008	C1	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Issued	15/685,942	8/24/2017	10,226,539	3/12/2019	Avelas Biosciences, Inc.	Cancer Imaging Compositions
48	AVS-008	C2	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Issued	16/264,296	1/31/2019	11052160	7/6/2021	Avelas Biosciences, Inc.	Cancer Imaging Compositions
49	AVS-008	C3	SELECTIVE DELIVERY MOLECULES AND METHODS OF USE	Pending	17/302,453	8/18/2022			Avelas Biosciences, Inc.	Cancer Imaging Compositions
50	AVS-009	EP	SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE	Pending	14788083.5	4/22/2014			Avelas Biosciences, Inc.	Therapeutics
51	AVS-009	HK	SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE	Pending	16110317.7	4/22/2014			Avelas Biosciences, Inc.	Therapeutics
52	AVS-009	C3	SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE	Pending	17/930259	9/7/2022			Avelas Biosciences, Inc.	Therapeutics
53	AVS-010	US	NERVE LABELING COMPOSITIONS AND USES THEREOF	Issued	16/466,259	6/3/2019	10994017	5/4/2021	Avelas Biosciences, Inc.	Nerve labeling
54	AVS-010	C1	NERVE LABELING COMPOSITIONS AND USES THEREOF	Pending	17/249,006	2/17/2021			Avelas Biosciences, Inc.	Nerve labeling
55	AVS-010	EP	NERVE LABELING COMPOSITIONS AND USES THEREOF	Pending	17875429.7	12/1/2017			Avelas Biosciences, Inc.	Nerve labeling
56	AVS-011	EPD1	RATIOMETRIC FLUORESCENCE IMAGING METHODS	Pending	21164870.4	3/25/2021			Avelas Biosciences, Inc.	Ratiometric imaging
57	AVS-011	KR	RATIOMETRIC FLUORESCENCE IMAGING METHODS	Pending	10-2019-7033078	4/5/2018			Avelas Biosciences, Inc.	Ratiometric imaging
58	AVS-011	CN	RATIOMETRIC FLUORESCENCE IMAGING METHODS	Pending	2018800381739	4/5/2018			Avelas Biosciences, Inc.	Ratiometric imaging
59	AVS-011	HK	RATIOMETRIC FLUORESCENCE IMAGING METHODS	Pending	42021040708.5	10/19/2021			Avelas Biosciences, Inc.	Ratiometric imaging
60	AVS-011	US	RATIOMETRIC FLUORESCENCE IMAGING METHODS	Issued	16/603,200	10/4/2019	11293868	4/5/2022	Avelas Biosciences, Inc.	Ratiometric imaging
61	AVS-011	EA	RATIOMETRIC FLUORESCENCE IMAGING METHODS	Pending	201992252	4/5/2018			Avelas Biosciences, Inc.	Ratiometric imaging

62	AVS-012	US	COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPUTIC AND IMAGING AGENTS	Pending	17/048,078	10/15/2020		Avelas Biosciences, Inc.	Therapeutics
63	AVS-012	EP	COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPUTIC AND IMAGING AGENTS	Pending	19789295.3	11/16/2020		Avelas Biosciences, Inc.	Therapeutics
64	AVS-012	HK	COMPOSITIONS AND METHODS FOR THE SELECTIVE DELIVERY OF THERAPUTIC AND IMAGING AGENTS	Pending	62021036762	8/11/2021		Avelas Biosciences, Inc.	Therapeutics
65	AVS-013	US	SELECTIVE DELIVERY OF THERAPUTIC AND IMAGING AGENTS	Pending	17/048,080	10/15/2020		Avelas Biosciences, Inc.	Therapeutics
66	AVS-014	WO	METHODS OF SURGICALLY REMOVING TUMOR CELLS	Pending	PCT/US2021/054313	10/8/2021		Avelas Biosciences, Inc.	AVB-620

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

CIVIL CODE § 1189

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California)
 County of San Diego)
 On March 9, 2023 before me, Christine E. Sayers, Notary Public
 Date Here Insert Name and Title of the Officer
 personally appeared Jay B. Lichter
 Name(s) of Signer(s)

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.



Signature Christine E. Sayers
 Signature of Notary Public

Place Notary Seal Above

OPTIONAL

Though this section is optional, completing this information can deter alteration of the document or fraudulent reattachment of this form to an unintended document.

Description of Attached Document

Title or Type of Document: _____ Document Date: _____

Number of Pages: _____ Signer(s) Other Than Named Above: _____

Capacity(ies) Claimed by Signer(s)

Signer's Name: _____

☐ Corporate Officer — Title(s): _____

☐ Partner — ☐ Limited ☐ General

☐ Individual ☐ Attorney in Fact

☐ Trustee ☐ Guardian or Conservator

☐ Other: _____

Signer Is Representing: _____

Signer's Name: _____

☐ Corporate Officer — Title(s): _____

☐ Partner — ☐ Limited ☐ General

☐ Individual ☐ Attorney in Fact

☐ Trustee ☐ Guardian or Conservator

☐ Other: _____

Signer Is Representing: _____

CALIFORNIA ALL-PURPOSE ACKNOWLEDGEMENT

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

STATE OF California)SS

COUNTY OF Santa Clara


On March 23 2023 before me, Carissa Kozacek Notary Public, personally appeared Michael Mady

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature



This area for official notarial seal.

OPTIONAL SECTION - NOT PART OF NOTARY ACKNOWLEDGEMENT CAPACITY CLAIMED BY SIGNER

Though statute does not require the Notary to fill in the data below, doing so may prove invaluable to persons relying on the documents.

- ☐ INDIVIDUAL
- ☐ CORPORATE OFFICER(S) TITLE(S)
- ☐ PARTNER(S) ☐ LIMITED ☐ GENERAL
- ☐ ATTORNEY-IN-FACT
- ☐ TRUSTEE(S)
- ☐ GUARDIAN/CONSERVATOR
- ☐ OTHER

SIGNER IS REPRESENTING:

Name of Person or Entity

Name of Person or Entity

OPTIONAL SECTION - NOT PART OF NOTARY ACKNOWLEDGEMENT

Though the data requested here is not required by law, it could prevent fraudulent reattachment of this form.

THIS CERTIFICATE MUST BE ATTACHED TO THE DOCUMENT DESCRIBED BELOW

TITLE OR TYPE OF DOCUMENT: _____

NUMBER OF PAGES _____ DATE OF DOCUMENT _____

SIGNER(S) OTHER THAN NAMED ABOVE _____

Reproduced by First American Title Company 11/2007

RECORDED: 09/19/2023

PATENT
REEL: 064958 FRAME: 0742